| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.017 | 0.7 |